Survaxm
Digestive System Neuroendocrine Neoplasm
Explore 22 assets in Digestive System Neuroendocrine Neoplasm →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06202066CT.gov Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Survaxm (this asset) | Roswell Park Cancer Institute | P2 | CCC · 53 |
| Oxodotreotide | National Cancer Institute (NCI) | P4 | BBB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Novartis Pharmaceuticals | P3 | BB |
| Eudemine Injection | University of Maryland, Baltimore | P4 | BB |
| Everolimus | RayzeBio, Inc. | P3 | BB |
| Edotreotide | Jiangsu HengRui Medicine Co., Ltd. | P3 | B |
| Lanreotide | RayzeBio, Inc. | P3 | B |
| Regorafenib | Translational Research in Oncology | P2 | B |
| Pasireotide | University of Maryland, Baltimore | P4 | B |
+23 more in the Digestive System Neuroendocrine Neoplasm cohort
Other indications for Survaxm
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glioblastoma | — | P2 | CCC · 55 |
| Cancer | — | P2 | CCC · 53 |
| Lung Neuroendocrine Neoplasm | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- OxodotreotideNational Cancer Institute (NCI)BBB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-Novartis PharmaceuticalsBB
- Eudemine InjectionUniversity of Maryland, BaltimoreBB
- EverolimusRayzeBio, Inc.BB
- EdotreotideJiangsu HengRui Medicine Co., Ltd.B
Citation
Floatz Terminal. Survaxm in Digestive System Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/survaxm-digestive-system-neuroendocrine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →